


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (previously presented) A compound of formula (1):



wherein:

R^4 and R^5 together are either $-S-C(R^6)=C(R^7)-$ or $-C(R^7)=C(R^6)-S-$;

R^6 and R^7 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy, carboxy, carbamoyl, (1-4C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, (1-4C)alkoxy and (1-4C)alkanoyl;

A is phenylene;

n is 0, 1 or 2;

R^1 is independently selected from halo, nitro, cyano, hydroxy, carboxy, carbamoyl, *N*-(1-4C)alkylcarbamoyl, *N,N*-((1-4C)alkyl)₂carbamoyl, sulphamoyl, *N*-(1-4C)alkylsulphamoyl, *N,N*-((1-4C)alkyl)₂sulphamoyl, $-S(O)_b(1-4C)alkyl$ (wherein b is 0, 1, or 2), $-OS(O)_2(1-4C)alkyl$, (1-4C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, (1-4C)alkoxy, (1-4C)alkanoyl, (1-4C)alkanoyloxy, hydroxy(1-4C)alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy and $-NH SO_2(1-4C)alkyl$;

or, when n is 2, the two R^1 groups, together with the carbon atoms of A to which they are attached, may form a 4 to 7 membered saturated ring optionally being substituted by one or two methyl groups;

one of R^2 and R^3 is selected from R_{Na} , and the other is selected from R_{Nb} ;

R_{Na} : (1-3C)alkyl, halo(1-3C)alkyl, dihalo(1-3)alkyl, trifluoromethyl, hydroxy(1-3C)alkyl, dihydroxy(2-3C)alkyl, cyano(1-3C)alkyl (optionally substituted on alkyl with hydroxy), methoxymethyl, ethoxymethyl, methoxyethyl, methoxymethoxymethyl, dimethoxyethyl, (hydroxy)(methoxy)ethyl, (amino)(hydroxy)(2-3C)alkyl, (aminocarbonyl)(hydroxy)(2-3C)alkyl, (methylaminocarbonyl)(hydroxy)(2-3C)alkyl, (dimethylaminocarbonyl)(hydroxy)(2-3C)alkyl,

(methylcarbonylamino)(hydroxy)(2-3C)alkyl, (methylS(O)_p)(hydroxy)(2-3C)alkyl (wherein p is 0, 1 or 2);

R_{Nb}: (1-4C)alkyl, halo(1-4C)alkyl, dihalo(1-4C)alkyl, trifluoromethyl, hydroxy(1-4C)alkyl, dihydroxy(2-4C)alkyl, trihydroxy(3-4C)alkyl, cyano(1-4C)alkyl (optionally substituted on alkyl with hydroxy), (1-4C)alkoxy(1-4C)alkyl, (1-4C)alkoxy(1-4C)alkoxy(1-4C)alkyl, di[(1-4C)alkoxy](2-4C)alkyl, (hydroxy)[(1-4C)alkoxy](2-4C)alkyl, (amino)(hydroxy)(2-4C)alkyl, (aminocarbonyl)(hydroxy)(2-4C)alkyl, ((1-4C)alkylaminocarbonyl)(hydroxy)(2-4C)alkyl, (di(1-4C)alkylaminocarbonyl)(hydroxy)(2-4C)alkyl, ((1-4C)alkylcarbonylamino)(hydroxy)(2-4C)alkyl, ((1-4C)alkylS(O)_p)(hydroxy)(2-4C)alkyl (wherein p is 0, 1 or 2);

wherein any alkyl or alkoxy group within any group in R_{Na} and R_{Nb} may also optionally be substituted on an available carbon atom with a hydroxy group (provided that said carbon atom is not already substituted by a group linked by a heteroatom);
provided that if R² is (1-3C)alkyl or (1-4C)alkyl then R³ is not (1-4C)alkyl or (1-3C)alkyl;
or a pharmaceutically acceptable salt thereof.

2. (previously presented) A compound of formula (1) as claimed in Claim 1, or a pharmaceutically acceptable salt thereof, wherein R² is selected from R_{Na}, and R³ is selected from R_{Nb}, wherein R_{Na} and R_{Nb} are as defined in Claim 1.

3. (cancelled)


4. (previously presented) A compound of formula (1) as claimed in Claim 1, or a pharmaceutically acceptable salt thereof, wherein n is 0.

5. (previously presented) A compound of formula (1) as claimed in Claim 1, or a pharmaceutically acceptable salt thereof, wherein R⁶ and R⁷ are independently selected from hydrogen and halo.

6. (previously presented) A compound of formula (1) as claimed in Claim 1, or a pharmaceutically acceptable salt thereof, wherein R⁶ and R⁷ are independently selected from hydrogen and chloro.

7. (previously presented) A compound of formula (1) as claimed in Claim 1, or a pharmaceutically acceptable salt thereof, wherein R_n is selected from (1-4C)alkyl, hydroxy(1-4C)alkyl, and (1-4C)alkoxy(1-4C)alkyl.

8. (previously presented) A compound of formula (1) as claimed in Claim 1, or a pharmaceutically acceptable salt thereof, which is a compound of formula (1A):




wherein R^1 to R^7 , A and n are as defined in claim 1.

9. (cancelled)


10. (original) A pharmaceutical composition which comprises a compound of the formula (1), or a pharmaceutically acceptable salt thereof, as claimed in claim 1 in association with a pharmaceutically-acceptable diluent or carrier.

11-15. (cancelled)

16. (currently amended) A process for the preparation of a compound of formula (1) as claimed in claim 1, which process comprises:
reacting an acid of the formula (2):



or an acid chloride or ester activated derivative thereof; with an amine of formula (3):



and thereafter if necessary:

- i) converting a compound of the formula (1) into another compound of the formula (1);
- ii) removing any protecting groups;
- iii) forming a pharmaceutically acceptable salt.

17. (previously presented) A compound of formula (1), or a pharmaceutically acceptable salt thereof, selected from:

2-chloro-*N*-{[(1*R*,2*R*)-1-[(methoxyacetyl)(methyl)amino]-2,3-dihydro-1*H*-inden-2-yl]-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide};

2-chloro-*N*-{[(1*R*,2*R*)-1-[(3-hydroxy-2-(hydroxymethyl)propanoyl](methyl)amino]-2,3-dihydro-1*H*-inden-2-yl]-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide};

ethyl 3-[[[(1*R*,2*R*)-2-[(2-chloro-6*H*-thieno[2,3-*b*]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1*H*-inden-1-yl](methyl)amino]-3-oxopropanoate;

2-[[[(1*R*,2*R*)-2-[(2-chloro-6*H*-thieno[2,3-*b*]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1*H*-inden-1-yl](methyl)amino]-2-oxoethyl acetate;

2-chloro-*N*-{[(1*R*,2*R*)-1-(glycoloyl(methyl)amino)-2,3-dihydro-1*H*-inden-2-yl]-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide};

2-chloro-*N*-{[(1*R*,2*R*)-1-(glyceroyl(methyl)amino)-2,3-dihydro-1*H*-inden-2-yl]-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide};

2-chloro-*N*-{[(1*R*,2*R*)-1-[(2*S*)-2,3-dihydroxypropanoyl](methyl)amino]-2,3-dihydro-1*H*-inden-2-yl]-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide};

2-chloro-*N*-{[(1*R*,2*R*)-1-[(2*R*)-2,3-dihydroxypropanoyl](methyl)amino]-2,3-dihydro-1*H*-inden-2-yl]-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide};

2-chloro-*N*-{[(1*R*,2*R*)-1-[(3-hydroxypropanoyl)(methyl)amino]-2,3-dihydro-1*H*-inden-2-yl]-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide};

2-chloro-*N*-{[(1*R*,2*R*)-1-(glycoloyl(2-hydroxyethyl)amino)-2,3-dihydro-1*H*-inden-2-yl]-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide};

2-chloro-*N*-{[(1*R*,2*R*)-1-[(2*R*)-2-hydroxypropanoyl](methyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide;

2-chloro-*N*-{[(1*R*,2*R*)-1-[(2*S*)-2-hydroxypropanoyl](methyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide;

2,3-dichloro-*N*-{[(1*R*,2*R*)-1-[(2*R*)-2,3-dihydroxypropanoyl](methyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-4*H*-thieno[3,2-*b*]pyrrole-5-carboxamide

2,3-dichloro-*N*-{[(1*R*,2*R*)-1-[(2*S*)-2,3-dihydroxypropanoyl](methyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-4*H*-thieno[3,2-*b*]pyrrole-5-carboxamide;

(2*S*)-*N*¹-{[(1*R*,2*R*)-2-[(2-chloro-6*H*-thieno[2,3-*b*]pyrrol-5-yl)carbonyl]amino}-2,3-dihydro-1*H*-inden-1-yl)-2-hydroxy-*N*¹-methylsuccinamide;

(2*S*)-*N*¹-{[(1*R*,2*R*)-2-[(2,3-dichloro-4*H*-thieno[3,2-*b*]pyrrol-5-yl)carbonyl]amino}-2,3-dihydro-1*H*-inden-1-yl)-2-hydroxy-*N*¹-methylsuccinamide;

2,3-dichloro-*N*-{[(1*R*,2*R*)-1-[(2*S*)-2-hydroxybutanoyl](methyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-4*H*-thieno[3,2-*b*]pyrrole-5-carboxamide;

2,3-dichloro-*N*-{[(1*R*,2*R*)-1-[(2*S*)-2-hydroxy-3-methylbutanoyl](methyl) amino]-2,3-dihydro-1*H*-inden-2-yl}-4*H*-thieno[3,2-*b*]pyrrole-5-carboxamide;

2,3-dichloro-*N*-{[(1*R*,2*R*)-1-[(2*S*)-4-(1,3-dioxo-1,3-dihydro-2*H*-isoindol-2-yl)-2-hydroxy butanoyl](methyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-4*H*-thieno[3,2-*b*]pyrrole-5-carboxamide;

2,3-dichloro-*N*-{[(1*R*,2*R*)-1-[(2*R*)-2-hydroxy-3-(methylthio)propanoyl](methyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-4*H*-thieno[3,2-*b*]pyrrole-5-carboxamide;

tert-butyl {(2*S*)-3-[[[(1*R*,2*R*)-2-[[[(2,3-dichloro-4*H*-thieno[3,2-*b*]pyrrol-5-yl)carbonyl]amino]-2,3-dihydro-1*H*-inden-1-yl)(methyl)amino]-2-hydroxy-3-oxopropyl]carbamate};

2,3-dichloro-*N*-{[(1*R*,2*R*)-1-[(2*S*)-3-cyano-2-hydroxypropanoyl](methyl) amino]-2,3-dihydro-1*H*-inden-2-yl}-4*H*-thieno[3,2-*b*]pyrrole-5-carboxamide;

N-{[(1*R*,2*R*)-1-[(*N*-acetylseryl)(methyl)amino]-2,3-dihydro-1*H*-inden-2-yl)-2-chloro-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide};

N-{[(1*R*,2*R*)-1-[(*N*-acetylseryl)(methyl)amino]-2,3-dihydro-1*H*-inden-2-yl)-2,3-dichloro-4*H*-thieno[3,2-*b*]pyrrole-5-carboxamide};

2,3-dichloro-*N*-{[(1*R*,2*R*)-1-[methyl(L-seryl)amino]-2,3-dihydro-1*H*-inden-2-yl)-4*H*-thieno[3,2-*b*]pyrrole-5-carboxamide hydrochloride};

2-chloro-*N*-{[(1*R*,2*R*)-1-[methyl(L-seryl)amino]-2,3-dihydro-1*H*-inden-2-yl)-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide hydrochloride};

(2*S*)-*N*¹-{[(1*R*,2*R*)-2-[(2-chloro-6*H*-thieno[2,3-*b*]pyrrol-5-yl)carbonyl]amino}-2,3-dihydro-1*H*-inden-1-yl)-2-hydroxy-*N*¹-methylpentanediamide;

(2S)-N¹-((1R,2R)-2-(((2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl)amino)-2,3-dihydro-1H-inden-1-yl)-2-hydroxy-N¹-methylpentanediamide;
 2-chloro-N-((1R,2R)-1-(((2S)-2-hydroxy-3-methoxypropanoyl)(methyl) amino)-2,3-dihydro-1H-inden-2-yl)-6H-thieno[2,3-b]pyrrole-5-carboxamide;
 2,3-dichloro-N-((1R,2R)-1-(((2S)-2-hydroxy-3-methoxypropanoyl)(methyl)amino)-2,3-dihydro-1H-inden-2-yl)-4H-thieno[3,2-b]pyrrole-5-carboxamide;
 2,3-dichloro-N-((1R,2R)-1-(((2R)-2-hydroxy-3-(methylsulfonyl)propanoyl)(methyl)amino)-2,3-dihydro-1H-inden-2-yl)-4H-thieno[3,2-b]pyrrole-5-carboxamide;
 N-((1R,2R)-1-(((2S)-3-amino-2-hydroxypropanoyl)(methyl)amino)-2,3-dihydro-1H-inden-2-yl)-2,3-dichloro-4H-thieno[3,2-b]pyrrole-5-carboxamide hydrochloride;
 (2S)-N¹-((1R,2R)-2-(((2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl)amino)-2,3-dihydro-1H-inden-1-yl)-2-hydroxy-N¹,N⁴-dimethylsuccinamide;
 (2S)-N¹-((1R,2R)-2-(((2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl) amino)-2,3-dihydro-1H-inden-1-yl)-2-hydroxy-N¹,N⁴,N⁴-trimethylsuccinamide;
 2-chloro-N-((1R,2R)-1-(glyceroyl(2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-2-yl)-6H-thieno[2,3-b]pyrrole-5-carboxamide;
 2-chloro-N-((1R,2R)-1-(((2R)-2,3-dihydroxypropanoyl)(2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-2-yl)-6H-thieno[2,3-b]pyrrole-5-carboxamide; and
 2-chloro-N-((1R,2R)-1-(((2S)-2,3-dihydroxypropanoyl)(2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-2-yl)-6H-thieno[2,3-b]pyrrole-5-carboxamide.

18. (withdrawn) A method of producing a glycogen phosphorylase inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (1) as claimed in claim 1.

19. (withdrawn) A method of treating type 2 diabetes, insulin resistance, syndrome X, hyperinsulinaemia, hyperglucagonaemia, cardiac ischaemia or obesity in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (1) as claimed in claim 1.

20. (withdrawn) A method of treating type 2 diabetes in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (1) as claimed in claim 1.